<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Raal, Frederick</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Human Monoclonal Antibody for PCSK9 Lowers Cholesterol and Is Well Tolerated</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-19</style></pages><abstract><style  face="normal" font="default" size="100%">Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that plays a pivotal role in cholesterol homeostasis by reducing expression of low-density lipoprotein cholesterol (LDL-C) receptors by the liver, leading to diminished hepatic clearance capacity for plasma LDL-C and increased LDL-C levels in the blood [Cohen JC et al. N Engl J Med 2006; Lagace TA et al. J Clin Invest 2006; Benjannet S et al. J Biol Chem 2010]. AMG 145 is a fully human monoclonal antibody that blocks PCSK9 binding to the LDL receptor, improving LDL-C clearance and reducing circulating LDL-C concentration [Raal F et al. Circulation 2012].</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>